Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 613

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial

Open access
Verma, Atul, Haines, David E., Boersma, Lucas V., Sood, Nitesh, Natale, Andrea, Marchlinski, Francis E., Calkins, Hugh, Sanders, Prashanthan, Packer, Douglas L., Kuck, Karl-Heinz, Hindricks, Gerhard, Onal, Birce, Cerkvenik, Jeffrey, Tada, Hiroshi, DeLurgio, David B., on behalf of the PULSED AF Investigators·2023·Circulation

Abstract

Background: Pulsed field ablation uses electrical pulses to cause nonthermal irreversible electroporation and induce cardiac cell death. Pulsed field ablation may have effectiveness comparable to traditional catheter ablation while preventing thermally mediated complications. Methods: The PULSED AF pivotal study (Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF) was a prospective, global, multicenter, nonrandomized, paired single-arm study in which patients with paroxysmal (n=150) or persistent (n=150) symptomatic atrial fibrillation (AF) refractory to class I or III antiarrhythmic drugs were treated with pulsed field ablation. All patients were monitored for 1 year using weekly and symptomatic transtelephonic monitoring; 3-, 6-, and 12-month ECGs; and 6- and 12-month 24-hour Holter monitoring. The primary effectiveness end point was freedom from a composite of acute procedural failure, arrhythmia recurrence, or antiarrhythmic escalation through 12 months, excluding a 3-month blanking period to allow recovery from the procedure. The primary safety end point was freedom from a composite of serious procedure- and device-related adverse events. Kaplan-Meier methods were used to evaluate the primary end points. Results: Pulsed field ablation was shown to be effective at 1 year in 66.2% (95% CI, 57.9 to 73.2) of patients with paroxysmal AF and 55.1% (95% CI, 46.7 to 62.7) of patients with persistent AF. The primary safety end point occurred in 1 patient (0.7%; 95% CI, 0.1 to 4.6) in both the paroxysmal and persistent AF cohorts. Conclusions: PULSED AF demonstrated a low rate of primary safety adverse events (0.7%) and provided effectiveness consistent with established ablation technologies using a novel irreversible electroporation energy to treat patients with AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04198701.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.123.063988

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 613

Metadata

Authors
Verma, A., Haines, D. E., Boersma, L. V., Sood, N., Natale, A., Marchlinski, F. E., Calkins, H., Sanders, P., Packer, D. L., Kuck, K.-H., Hindricks, G., Onal, B., Cerkvenik, J., Tada, H., DeLurgio, D. B., & on behalf of the PULSED AF Investigators
Venue
Circulation
Published
2023-05-09
Volume
147
Issue
19
Pages
1422-1432
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W4323294621
Cited by
613
References
38
FWCI
107.83
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. https://app.cochat.ai/papers/10.1161/circulationaha.123.063988
The paper
Verma, A., Haines, D. E., Boersma, L. V., Sood, N., Natale, A., Marchlinski, F. E., Calkins, H., Sanders, P., Packer, D. L., Kuck, K.-H., Hindricks, G., Onal, B., Cerkvenik, J., Tada, H., DeLurgio, D. B., & on behalf of the PULSED AF Investigators. (2023). Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation. https://doi.org/10.1161/circulationaha.123.063988

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.